Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Amgen | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Amgen

Revenues up 9% in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Amgen

1Q Revenues: $4.0 billion (+9%)

1Q Earnings: $1.2 billion (+5%)

Comments: U.S. and International product sales were up 8% to $3.0 billion and $904 million, respectively. Xgeva sales were $153 million, up 14%. Prolia sales were $88 million up 9%. Combined Neulasta and Neupogen sales increased 9% to $1.3 billion. Enbrel sales increased 7% to $938 million. Aranesp sales were down 11% to $518 million, primarily due to a decline in unit demand, while Epogen sales dropped 17% to $446 million, reflecting the impact of label and reimbursement changes.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters